Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program

• Published in: Frontiers in immunology Vol. 15; p. 1390022
• Main Authors: van Leeuwen, Leanne P M, Grobben, Marloes, GeurtsvanKessel, Corine H, Ellerbroek, Pauline M, de Bree, Godelieve J, Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank L, van Gils, Marit J, de Vries, Rory D, Dalm, Virgil A S H
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 18.04.2024
• Subjects: 2019-nCoV Vaccine mRNA-1273 - immunology; Adolescent; Adult; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; Antibodies, Viral - immunology; booster vaccination; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Female; Follow-Up Studies; Humans; Immunization, Secondary; immunogenicity; Immunogenicity, Vaccine; Immunoglobulin G - blood; Immunoglobulin G - immunology; Immunologic Deficiency Syndromes - immunology; Immunology; inborn errors of immunity; Male; Middle Aged; mRNA-1273 COVID-19 vaccine; primary immunodeficiency disorders; Prospective Studies; SARS-CoV-2; SARS-CoV-2 - immunology; Spike Glycoprotein, Coronavirus - immunology; T-Lymphocytes - immunology; Vaccination; Young Adult; SARS-CoV-2; antibody response; booster vaccination; mRNA-1273 COVID-19 vaccine; inborn errors of immunity; primary immunodeficiency disorders; immunogenicity; T-cell response
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1390022

Previous studies have demonstrated that the majority of patients with an inborn error of immunity (IEI) develop a spike (S)-specific IgG antibody and T-cell response after two doses of the mRNA-1273 COVID-19 vaccine, but little is known about the response to a booster vaccination. We studied the immune responses 8 weeks after booster vaccination with mRNA-based COVID-19 vaccines in 171 IEI patients. Moreover, we evaluated the clinical outcomes in these patients one year after the start of the Dutch COVID-19 vaccination campaign. This study was embedded in a large prospective multicenter study investigating the immunogenicity of COVID-19 mRNA-based vaccines in IEI (VACOPID study). Blood samples were taken from 244 participants 8 weeks after booster vaccination. These participants included 171 IEI patients (X-linked agammaglobulinemia (XLA;N=11), combined immunodeficiency (CID;N=4), common variable immunodeficiency (CVID;N=45), isolated or undefined antibody deficiencies (N=108) and phagocyte defects (N=3)) and 73 controls. SARS-CoV-2-specific IgG titers, neutralizing antibodies, and T-cell responses were evaluated. One year after the start of the COVID-19 vaccination program, 334 study participants (239 IEI patients and 95 controls) completed a questionnaire to supplement their clinical data focusing on SARS-CoV-2 infections. After booster vaccination, S-specific IgG titers increased in all COVID-19 naive IEI cohorts and controls, when compared to titers at 6 months after the priming regimen. The fold-increases did not differ between controls and IEI cohorts. SARS-CoV-2-specific T-cell responses also increased equally in all cohorts after booster vaccination compared to 6 months after the priming regimen. Most SARS-CoV-2 infections during the study period occurred in the period when the Omicron variant had become dominant. The clinical course of these infections was mild, although IEI patients experienced more frequent fever and dyspnea compared to controls and their symptoms persisted longer. Our study demonstrates that mRNA-based booster vaccination induces robust recall of memory B-cell and T-cell responses in most IEI patients. One-year clinical follow-up demonstrated that SARS-CoV-2 infections in IEI patients were mild. Given our results, we support booster campaigns with newer variant-specific COVID-19 booster vaccines to IEI patients with milder phenotypes.